Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 69.00
Bid: 68.00
Ask: 70.00
Change: 0.00 (0.00%)
Spread: 2.00 (2.941%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 69.00
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directors Dealing Notification

18 Apr 2018 17:08

RNS Number : 3812L
NetScientific PLC
18 April 2018
 

18 April 2018

NetScientific plc

 

Directors Dealing Notification

 

NetScientific plc (AIM:NSCI) (the "Company"), the transatlantic healthcare IP commercialisation group, announces that on 17 April 2018 it received notification that Sir Richard Sykes, Barry Wilson, and Steve Smith (the "Directors"), subscribed for New Ordinary Shares (the "Shares") in the NetScientific Placing and Subscription (the "Placing") at a price of 52.5 pence per Share, with the Shares admitted to trading on AIM on 17 April 2018.

 

The details of the Directors' shareholdings in the Company following the Placing are as follows:

 

 

No. of Ordinary Shares as at 28 March 2018

(date of announcement of conditional Placing)

No. of New Ordinary Shares subscribed

No. of Ordinary Shares as at Admission

Percentage of enlarged share capital as at Admission

Sir Richard Sykes

62,500

30,952

93,452

0.12%

Barry Wilson

36,358

30,952

67,310

0.09%

Professor Stephen Smith

-

28,571

28,571

0.04%

 

The total number of voting rights in NetScientific is 78,561,866.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1

 Details of the person discharging managerial responsibility / person closely associated 

 

a)

 

 Name

 

 Sir Richard Sykes

2

 Reason for the notification

 

a)

 

 Position/status

 

 PDMR (Non-Executive Director - Chairman)

 

b)

 

 Initial notification/amendment

 

 Initial notification

3

 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 NetScientific plc

 

b)

 

LEI

 

 213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 Ordinary shares

 

Identification code

 

 GB00B9F4MT28

 

b)

 

Nature of transaction

 

 Participation in placing

 

c)

 

 Price(s) and volume(s)

 

 Price(s)

 

 Volume(s)

 

 £0.525 per share

 

 30,952

 

d)

 

Aggregated information

 

Aggregated volume

 

 30,952

 

Price

 

 £0.525 per share

 

e)

 

Date of transaction

 

 17 April 2018

 

f)

 

Place of transaction

 

 UK AIM

 

 

1

 Details of the person discharging managerial responsibility / person closely associated 

 

a)

 

 Name

 

 Barry Wilson

2

 Reason for the notification

 

a)

 

 Position/status

 

 PDMR (Non-Executive Director)

 

b)

 

 Initial notification/amendment

 

 Initial notification

3

 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 NetScientific plc

 

b)

 

LEI

 

 213800N5WD46G1Y7I458

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 Ordinary shares

 

Identification code

 

 GB00B9F4MT28

 

b)

 

Nature of transaction

 

 Participation in placing

 

c)

 

 Price(s) and volume(s)

 

 Price(s)

 

 Volume(s)

 

 £0.525 per share

 

 30,952

 

d)

 

Aggregated information

 

Aggregated volume

 

 30,952

 

Price

 

 £0.525 per share

 

e)

 

Date of transaction

 

 17 April 2018

 

f)

 

Place of transaction

 

 UK AIM

 

 

1

 Details of the person discharging managerial responsibility / person closely associated 

 

a)

 

 Name

 

 Steve Smith

2

 Reason for the notification

 

a)

 

 Position/status

 

 PDMR (Non-Executive Director)

 

b)

 

 Initial notification/amendment

 

 Initial notification

3

 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 NetScientific plc

 

b)

 

LEI

 

 213800N5WD46G1Y7I458

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

 

 Ordinary shares

 

Identification code

 

 GB00B9F4MT28

 

b)

 

Nature of transaction

 

 Participation in placing

 

c)

 

 Price(s) and volume(s)

 

 Price(s)

 

 Volume(s)

 

 £0.525 per share

 

 28,571

 

d)

 

Aggregated information

 

Aggregated volume

 

 28,571

 

Price

 

 £0.525 per share

 

e)

 

Date of transaction

 

 17 April 2018

 

f)

 

Place of transaction

 

 UK AIM

 

 

For more information, please contact:

 

NetScientific plc

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800

Consilium Strategic Communications

Mary-Jane Elliott/Jessica Hodgson

Chris Welsh/Laura Thornton

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Bookrunner)

Jonathan Senior/David Arch/Ben Maddison

 Tel: +44 (0) 20 7710 7600

Liberum Capital Limited (Placing Agent)

David Parsons/Christopher Britton/Bidhi Bhoma/Euan Brown

Tel: +44 (0)20 3709 5700

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHGGUAUCUPRGQR
Date   Source Headline
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn
14th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 20227:00 amRNSBoard Change
7th Nov 20223:40 pmRNSPDS reports presentation of data at cancer society
20th Oct 20227:00 amRNSEMV Capital secures investment in Ventive
11th Oct 20224:00 pmRNSPDS Update
3rd Oct 20221:56 pmRNSPDS completes End-of-Phase 2 meeting with FDA
30th Sep 20227:00 amRNSHalf-year Report
25th Aug 20227:00 amRNSPDS Completes $35 Million Financing Agreement
16th Aug 20227:00 amRNSAcquisition of 30% Vortex stake & new Vortex CEO
8th Aug 20224:45 pmRNSPDS Reports Q2 2022 Results & Business Update
29th Jun 20222:05 pmRNSResult of AGM
28th Jun 20229:15 amRNSHolding(s) in Company
27th Jun 20228:30 amRNSDirector/PDMR Shareholding
27th Jun 20228:30 amRNSHolding(s) in Company
22nd Jun 20227:00 amRNSResult of Placing and Total Voting Rights
21st Jun 20224:41 pmRNSProposed Placing to raise at least £1.5 million
17th Jun 202212:00 pmRNSNetScientific to increase Q-Bot stake to 23.7%
15th Jun 20227:00 amRNSQ-Bot secures £1.6m of investment to fund growth
7th Jun 202211:07 amRNSNotice of AGM and Annual Report & Accounts
6th Jun 20227:00 amRNSPDS Granted FDA Fast Track Designation for PDS0101
27th May 20222:39 pmRNSPDS Biotech - new data for ongoing clinical trials
19th May 20227:00 amRNSGeneral Counsel Strategic Hire & Grant of Options
16th May 20227:00 amRNSProAxsis Update
12th May 20227:00 amRNSFinal Results
11th May 20223:46 pmRNSPDS Reports Q1 2022 Results & Business Update
9th May 20227:00 amRNSNotice of Results & Investor Presentation
6th May 20227:00 amRNSAcquisition of 30% of Vortex Biotech Holdings
25th Apr 20222:05 pmRNSSecond Price Monitoring Extn
25th Apr 20222:00 pmRNSPrice Monitoring Extension
25th Apr 202211:05 amRNSSecond Price Monitoring Extn
25th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 20221:24 pmRNSPDS Provides Business Update & Full-Year Results
4th Mar 20227:30 amRNSPublication of Shareholder Newsletter
24th Feb 20224:45 pmRNSPDS Announces Preliminary Safety Data on PDS0101
15th Feb 20222:32 pmRNSPDS Clinical Trial with Mayo Clinic
2nd Feb 20223:00 pmRNSPDS Phase 2 Trial Update
28th Jan 20228:45 amRNSPDS Announces Preclinical Data for PDS0202 Vaccine
18th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20222:20 pmRNSPDS Granted Novel HPV16 Immunotherapy Patent
10th Jan 20227:00 amRNSProAxsis CEO End of Year Update
29th Dec 20218:47 amRNSIssue of Equity
21st Dec 20211:59 pmRNSTR-1: Form for notification of major holdings
21st Dec 20217:00 amRNSQ-Bot Investment and Share Acquisition
20th Dec 20217:00 amRNSAcquisition of majority stake in Cetromed
13th Dec 20217:00 amRNSMartlet Capital Update
6th Dec 20212:53 pmRNSPDS Phase 2 Clinical Trial Update
26th Nov 20217:00 amRNS$1million investment in portfolio company, EpiBone

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.